CHIEF EXECUTIVE OFFICER S STATEMENT I am pleased to report the Group s interim results for the six-month period ended 31 October 2023. During the period, Scancell.
Scancell Holding: Catalysts are coming into view, says investment bank proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Cancer and infectious disease immunotherapies developer Scancell Holdings (Oxford, UK), has announced preliminary immunogenicity data from its Phase 1 COVIDITY clinical trial. Click to read more.